Merged with Trawsfynydd Therapeutics, Inc. in Jun 2024
ONTX - Onconova Therapeutics, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Newtown,
United States
Type: Equity
ONTX price evolution
ONTX
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $20.82 | $25.24 | $29.73 | $34.22 |
| Short term investments | ||||
| Net receivables | $0.02 | $0.02 | $0.02 | $0.02 |
| Inventory | ||||
| Total current assets | $22.66 | $27.01 | $30.45 | $35.04 |
| Long term investments | ||||
| Property, plant & equipment | $0.02 | $0.03 | $0.02 | $0.02 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $0.02 | $0.03 | $0.02 | $0.02 |
| Total investments | ||||
| Total assets | $22.68 | $27.04 | $30.47 | $35.06 |
| Current liabilities | ||||
| Accounts payable | $5.62 | $6.15 | $5.07 | $4.9 |
| Deferred revenue | $3.02 | $3.07 | $3.13 | $3.19 |
| Short long term debt | ||||
| Total current liabilities | $9.22 | $9.67 | $8.67 | $9.22 |
| Long term debt | ||||
| Total noncurrent liabilities | $2.79 | $2.85 | $2.9 | $2.96 |
| Total debt | ||||
| Total liabilities | $12.01 | $12.52 | $11.57 | $12.19 |
| Shareholders' equity | ||||
| Retained earnings | -$482.63 | -$478.45 | -$473.71 | -$469.46 |
| Other shareholder equity | -$0.02 | -$0.03 | -$0.03 | -$0.03 |
| Total shareholder equity | $10.67 | $14.52 | $18.9 | $22.88 |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $20.82 | $38.76 | $55.07 | $19.02 |
| Short term investments | ||||
| Net receivables | $0.02 | $0.03 | $0.03 | $0.04 |
| Inventory | ||||
| Total current assets | $22.66 | $39.35 | $55.43 | $19.78 |
| Long term investments | ||||
| Property, plant & equipment | $0.02 | $0.02 | $0.04 | $0.05 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $0.02 | $0.03 | $0.05 | $0.2 |
| Total investments | ||||
| Total assets | $22.68 | $39.37 | $55.48 | $19.99 |
| Current liabilities | ||||
| Accounts payable | $5.62 | $3.86 | $2.76 | $4.83 |
| Deferred revenue | $3.02 | $3.24 | $3.47 | $3.69 |
| Short long term debt | ||||
| Total current liabilities | $9.22 | $8.05 | $6.12 | $10.02 |
| Long term debt | ||||
| Total noncurrent liabilities | $2.79 | $3.02 | $3.24 | $3.79 |
| Total debt | ||||
| Total liabilities | $12.01 | $11.06 | $9.36 | $13.81 |
| Shareholders' equity | ||||
| Retained earnings | -$482.63 | -$463.68 | -$444.72 | -$428.56 |
| Other shareholder equity | -$0.02 | -$0.03 | -$0.01 | $0.01 |
| Total shareholder equity | $10.67 | $28.31 | $46.12 | $6.17 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $0.06 | $0.06 | $0.06 | $0.06 |
| Cost of revenue | ||||
| Gross Profit | $0.06 | $0.06 | $0.06 | $0.06 |
| Operating activities | ||||
| Research & development | $2.43 | $2.46 | $2.46 | $4.08 |
| Selling, general & administrative | $2.08 | $2.69 | $2.21 | $2.11 |
| Total operating expenses | $4.52 | $5.15 | $4.67 | $6.19 |
| Operating income | -$4.46 | -$5.09 | -$4.61 | -$6.14 |
| Income from continuing operations | ||||
| EBIT | -$4.18 | -$4.74 | -$4.25 | -$5.78 |
| Income tax expense | ||||
| Interest expense | ||||
| Net income | ||||
| Net income | -$4.18 | -$4.74 | -$4.25 | -$5.78 |
| Income (for common shares) | -$4.18 | -$4.74 | -$4.25 | -$5.78 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Jan 2022 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $0.23 | $0.23 | $0.23 | |
| Cost of revenue | ||||
| Gross Profit | $0.23 | $0.23 | $0.23 | |
| Operating activities | ||||
| Research & development | $11.43 | $11.41 | $16.9 | |
| Selling, general & administrative | $9.09 | $8.45 | $8.33 | |
| Total operating expenses | $20.52 | $19.85 | $25.22 | |
| Operating income | -$20.3 | -$19.63 | -$24.99 | |
| Income from continuing operations | ||||
| EBIT | -$18.95 | -$18.96 | -$25.15 | |
| Income tax expense | $0 | |||
| Interest expense | ||||
| Net income | ||||
| Net income | -$18.95 | -$18.96 | -$25.16 | |
| Income (for common shares) | -$18.95 | -$18.96 | -$25.16 | |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Net income | -$4.18 | -$4.74 | -$4.25 | -$5.78 |
| Operating activities | ||||
| Depreciation | $0 | $0.01 | $0 | $0 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $0.33 | $0.36 | $0.27 | $0.34 |
| Total cash flows from operations | -$4.43 | -$4.47 | -$4.49 | -$4.54 |
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | ||||
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | ||||
| Effect of exchange rate | $0.01 | -$0 | -$0 | $0.01 |
| Change in cash and equivalents | -$4.42 | -$4.49 | -$4.49 | -$4.54 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$18.95 | -$18.96 | -$16.16 | -$25.16 |
| Operating activities | ||||
| Depreciation | $0.02 | $0.01 | $0.01 | $0.01 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $1.3 | $1.17 | $0.58 | $0.37 |
| Total cash flows from operations | -$17.93 | -$16.29 | -$19.49 | -$23.07 |
| Investing activities | ||||
| Capital expenditures | -$0.01 | -$0.01 | ||
| Investments | ||||
| Total cash flows from investing | -$0.01 | -$0.01 | ||
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $55.56 | $19.36 | ||
| Net borrowings | ||||
| Total cash flows from financing | $55.56 | $19.36 | ||
| Effect of exchange rate | $0.01 | -$0.02 | -$0.03 | $0.03 |
| Change in cash and equivalents | -$17.94 | -$16.31 | $36.05 | -$3.7 |
News
Fundamentals
| Market cap | N/A |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | N/A |
| Revenue | $226.00K |
|---|---|
| EBITDA | -$18.93M |
| EBIT | -$18.95M |
| Net Income | -$18.95M |
| Revenue Q/Q | 0.00% |
| Revenue Y/Y | 0.00% |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | -65.76% |
| ROE | -113.18% |
| Debt/Equity | 1.13 |
|---|---|
| Net debt/EBITDA | 0.47 |
| Current ratio | 2.46 |
| Quick ratio | 2.46 |